Sonidegib improved quality of life in patients with advanced basal cell carcinoma: Results from the phase 2 Basal cell carcinoma outcomes with LDE225 treatment trial through 73 weeks.
(2023) JAAD international — Vol. 10, p. 31-33 (2023)
Files
2023_Migden_JAAD_Int.pdf
Open Access - Adobe PDF
- 328.18 KB
Details
- Authors
- Abstract
- TO THE EDITOR: Basal cell carcinoma (BCC) is the most common US skin malignancy, and its European incidence is increasing. Patients with locally advanced (laBCC) or metastatic BCC (mBCC) require treatment options other than traditional surgery and radiation, which can produce scarring and disfigurement that cause psychological stress. Sonidegib is a Hedgehog pathway inhibitor approved to treat advanced BCC (Switzerland and Australia) and laBCC (United States and European Union). Limited data exist regarding quality of life (QoL) in patients with advanced BCC.2 Assessments of QoL in patients with laBCC and mBCC were conducted during the Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT) trial for sonidegib. [...]
- Affiliations
Citations
Migden, M., Loquai, C., Robert, C., Baurain, J.-F., Squittieri, N., Arntz, R., Dierlamm, J., & Dréno, B. (2023). Sonidegib improved quality of life in patients with advanced basal cell carcinoma: Results from the phase 2 Basal cell carcinoma outcomes with LDE225 treatment trial through 73 weeks. JAAD international, 10, 31-33. https://doi.org/10.1016/j.jdin.2022.08.027 (Original work published 2023)